Interestingly, PTX-3 has been suggested as a novel biomarker of hypertension [29], which is a common toxic effect of bevacizumab that is associated with improvement of the anti-angiogenic treatment effect [30, 31]. This evidence concerns the gene PTX3 and hypertensive disorder.